Home › Trial NCT06290817
Orelabrutinib Combined With R-CDOP for DLBCL Patients With High-risk of CNS Relapse Defined by CNS-IPI
- Trial IDNCT06290817
- StatusUnknown
- PhasePhase 2
- Study typeInterventional
- SponsorSecond Affiliated Hospital, Zhejiang University, School of Medicine
- Enrollment62
- Start date2023-03-30
- ConditionsDiffuse Large B-cell Lymphoma
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.